The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive

References

• OlayioyeMANeveRMLaneHAHynesNEThe ErbB signaling network: receptor heterodimerization in development and cancerEMBO J200019133159316710880430
   PubMed Web of Science ®Google Scholar
• YardenYThe EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunitiesEur J Cancer200137Suppl 4S3S8
   PubMed Web of Science ®Google Scholar
• GreulichHChenTHFengWOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsPLoS Med2005211e31316187797
   PubMed Web of Science ®Google Scholar
• LinggiBCarpenterGErbB receptors: new insights on mechanisms and biologyTrends Cell Biol2006161264965617085050
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• RosellRTaronMReguartNIslaDMoranTEpidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathwayClin Cancer Res200612247222723117189393
   PubMedGoogle Scholar
• ValleyCCArndt-JovinDJKaredlaNEnhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancerMol Biol Cell201526224087409926337388
   PubMedGoogle Scholar
• YmerSIGreenallSACvrljevicAGlioma specific extracellular missense mutations in the first cysteine rich region of epidermal growth factor receptor (EGFR) initiate ligand independent activationCancers (Basel)2011322032204924212795
   PubMedGoogle Scholar
• LeeJCVivancoIBeroukhimREpidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domainPLoS Med2006312e48517177598
   PubMedGoogle Scholar
• VivancoIRobinsHIRohleDDifferential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsCancer Discov20122545847122588883
   PubMed Web of Science ®Google Scholar
• Sanchez-MartinFJBellosilloBGelabert-BaldrichMThe first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancerClin Cancer Res201622133260326726888827
   PubMedGoogle Scholar
• KellerJNimnualASVargheseMSVanHeystKAHaymanMJChanELA novel EGFR extracellular domain mutant, EGFRdelta768, possesses distinct biological and biochemical properties in neuroblastomaMol Cancer Res201614874075227216155
   PubMedGoogle Scholar
• ArenaSBellosilloBSiravegnaGEmergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancerClin Cancer Res20152192157216625623215
   PubMed Web of Science ®Google Scholar
• JiaYYunCHParkEOvercoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsNature2016534760512913227251290
   PubMed Web of Science ®Google Scholar
• JaiswalBSKljavinNMStawiskiEWOncogenic ERBB3 mutations in human cancersCancer Cell201323560361723680147
   PubMed Web of Science ®Google Scholar
• GreulichHKaplanBMertinsPFunctional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2Proc Natl Acad Sci U S A201210936144761448122908275
   PubMed Web of Science ®Google Scholar
• WarmuthMKimSGuXJXiaGAdrianFBa/F3 cells and their use in kinase drug discoveryCurr Opin Oncol2007191556017133113
   PubMed Web of Science ®Google Scholar
• BannoETogashiYNakamuraYSensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?Cancer Sci201610781134114027240419
   PubMed Web of Science ®Google Scholar
• WangRZhangYPanYComprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patientsOncotarget2015633343003430826486077
   PubMedGoogle Scholar
• LiaoRGJungJTchaichaJInhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinomaCancer Res201373165195520523786770
   PubMed Web of Science ®Google Scholar
• StarczynowskiDTLockwoodWWDelehouzeeSTRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancerJ Clin Invest2011121104095410521911935
   PubMed Web of Science ®Google Scholar
• MartinelliEDe PalmaROrdituraMDe VitaFCiardielloFAnti-epidermal growth factor receptor monoclonal antibodies in cancer therapyClin Exp Immunol2009158119
   PubMed Web of Science ®Google Scholar
• JiangJGreulichHJannePASellersWRMeyersonMGriffinJDEpidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progressionCancer Res200565198968897416204070
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• GaughanEMCostaDBGenotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesTher Adv Med Oncol20113311312521904575
   PubMedGoogle Scholar
• YangJCSequistLVGeaterSLClinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6Lancet Oncol201516783083826051236
   PubMed Web of Science ®Google Scholar
• AckermanAGoldsteinMAKobayashiSCostaDBEGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancerJ Thorac Oncol2012710e19e2022982663
   PubMed Web of Science ®Google Scholar
• GallantJNSheehanJHShaverTMEGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinibCancer Discov20155111155116326286086
   PubMedGoogle Scholar
• HeMCapellettiMNafaKEGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaClin Cancer Res20121861790179722190593
   PubMed Web of Science ®Google Scholar
• WuJYYuCJChangYCYangCHShihJYYangPCEffectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancerClin Cancer Res201117113812382121531810
   PubMed Web of Science ®Google Scholar
• GazdarARobinsonLOliverDHereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutationsJ Thorac Oncol20149445646324736066
   PubMed Web of Science ®Google Scholar
• TanizakiJErcanDCapellettiMIdentification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2Cancer Res201575153139314626048680
   PubMedGoogle Scholar
• ParsonsDWJonesSZhangXAn integrated genomic analysis of human glioblastoma multiformeScience200832158971807181218772396
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature200845572161061106818772890
   PubMed Web of Science ®Google Scholar
• TakagiMMiyoshiTNagashimaYNovel heterozygous mutation in the extracellular domain of FGFR1 associated with Hartsfield syndromeHum Genome Var201631603427790375
   PubMedGoogle Scholar